Section 4 of 6
Clinical evidence
396 evidence topics · 52 sources
Study summaries
ONWARD1
Objective
Objective and questions in the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2024-07-25” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-09-19” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-11-20” (opens the source at this quote in a new tab)
“First Posted 2024-09-19” (opens the source at this quote in a new tab)
“Last Update Posted 2026-10-28” (opens the source at this quote in a new tab)
Completion dates estimated at registration, September 2024, superseded in June 2025
Results posting status and certification date in the ClinicalTrials.gov record
Countries of trial sites in the ClinicalTrials.gov record
| Country | First site listed for the country in the record |
|---|---|
| United States | “Phoenix, Arizona, United States, 85032” |
| Australia | “Kogarah, New South Wales, Australia, 2217” |
| Bulgaria | “Gabrovo, Bulgaria, 5300” |
| Canada | “Edmonton, Alberta, Canada, T5J 3S9” |
| Czechia | “Kutná Hora, Czechia, 28401” |
| Germany | “Tübingen, Baden-Wurttemberg, Germany, 72070” |
| Japan | “Fukuoka, Fukuoka-shi, Japan, 814-0180” |
| Poland | “Gdansk, Poland, 80-546” |
| Portugal | “Lisbon, Portugal, 1998-018” |
| South Korea | “Busan, South Korea, 49241” |
Country removed from the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Removed location countries (removedCountries) | “Belgium” |
Countries listed for ESK-001-016 and enrollment from Japan in the topline webcast presentation
Enrollment period and number of sites across ONWARD1 and ONWARD2
Study design
Design in the ClinicalTrials.gov record
“Primary Purpose : Treatment” (opens the source at this quote in a new tab)
“Allocation : Randomized” (opens the source at this quote in a new tab)
“Interventional Model : Parallel Assignment” (opens the source at this quote in a new tab)
“Masking : Quadruple” (opens the source at this quote in a new tab)
Parallel 24-week design of ONWARD1 and ONWARD2
Replicate design of ONWARD1 and ONWARD2
Placebo rollover to envudeucitinib at week 16 and treatment periods in the design schematic
Eligibility for the ONWARD3 long-term extension after week 24
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |
Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Participants with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |
Washout periods and prior treatment response in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |
Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in November 2024
Cardiac, infection, and laboratory exclusion criteria in the ClinicalTrials.gov record
Malignancy, vaccination, surgery, and psychiatric exclusion criteria in the ClinicalTrials.gov record
Key inclusion and exclusion criteria for ONWARD1 and ONWARD2 in the topline webcast presentation
“Total body weight >40 kg (88 lb )” (opens the source at this quote in a new tab)
“Plaques covering ≥10% of BSA at Screening and Day 1” (opens the source at this quote in a new tab)
“PASI ≥12 at Screening and Day 1” (opens the source at this quote in a new tab)
“sPGA ≥3 at Screening and Day 1” (opens the source at this quote in a new tab)
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Quoted record |
|---|---|
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |
Dose and randomization ratio across ONWARD1 and ONWARD2
No fasting requirement in ONWARD1 and ONWARD2
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Primary outcome in the ClinicalTrials.gov record
Secondary outcomes in the ClinicalTrials.gov record
Planned co-primary endpoints of ONWARD1 and ONWARD2
Co-primary, key secondary, and safety endpoints of ONWARD1 and ONWARD2 in the congress poster
Definitions of PASI and sPGA response thresholds in the congress presentation
Regulatory guidance on PASI as a primary endpoint and its pairing with a global score
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Planned enrollment at registration
Planned enrollment of approximately 840 participants per trial
Description of analysis sets
Intention-to-treat analysis of response endpoints in ONWARD1 and ONWARD2
Mixed model for repeated measures for itch in ONWARD1 and ONWARD2
Pooled safety analysis population of ONWARD1 and ONWARD2
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD1
| Characteristic | Envudeucitinib 40 mg BID, n = 459 | Placebo, n = 230 | Apremilast 30 mg BID, n = 223 |
|---|---|---|---|
| Age, years, mean (SD) | “49.1 (13.4)” | “49.2 (13.3)” | “47.7 (11.8)” |
| Age group, ≥65 years, n (%) | “61 (13.3)” | “27 (11.7)” | “15 (6.7)” |
| Sex, male, n (%) | “300 (65.4)” | “156 (67.8)” | “152 (68.2)” |
| Race, White, n (%) | “358 (78.0)” | “182 (79.1)” | “177 (79.4)” |
| Race, Asian, n (%) | “68 (14.8)” | “28 (12.2)” | “30 (13.5)” |
| Race, other, n (%) | “33 (7.2)” | “20 (8.7)” | “16 (7.2)” |
| Weight, kg, mean (SD) | “90.4 (24.0)” | “91.0 (24.3)” | “88.9 (21.0)” |
| BMI, kg/m2, mean (SD) | “30.6 (7.2)” | “30.6 (7.2)” | “29.8 (6.5)” |
| Duration of disease, years, mean (SD) | “19.9 (13.5)” | “19.5 (13.3)” | “17.2 (11.8)” |
| PASI, mean (SD) | “20.4 (8.0)” | “19.9 (7.5)” | “20.3 (6.9)” |
| sPGA of 4, n (%) | “129 (28.1)” | “57 (24.8)” | “61 (27.4)” |
| BSA % affected, mean (SD) | “25.8 (15.8)” | “26.2 (16.0)” | “25.2 (14.9)” |
| DLQI, mean (SD) | “10.6 (6.5)” | “10.1 (6.7)” | “10.8 (6.8)” |
| Worst pruritus NRS, mean (SD) | “6.1 (2.7)” | “6.0 (2.7)” | “6.3 (2.6)” |
| Prior systemic psoriasis treatment, n (%) | “221 (48.1)” | “113 (49.1)” | “107 (48.0)” |
Balance across arms and definitions of other race and prior systemic treatment in the ONWARD1 and ONWARD2 baseline table
Baseline itch and scalp involvement by arm in ONWARD1
| Characteristic | Envudeucitinib 40 mg BID, N = 459 | Placebo, N = 230 | Apremilast 30 mg BID, N = 223 |
|---|---|---|---|
| Worst pruritus NRS ≥1, n (%) | “420 (91.5)” | “210 (91.3)” | “210 (94.2)” |
| Worst pruritus NRS ≥4, n (%) | “353 (76.9)” | “175 (76.1)” | “176 (78.9)” |
| ss-PGA ≥3, n | “274” | “135” | “150” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “213 (77.7)” | “102 (75.6)” | “124 (82.7)” |
Baseline characteristics averaged across ONWARD1 and ONWARD2, including prior systemic and prior biologic use
“Data based on average from both studies” (opens the source at this quote in a new tab)
“64 - 67% Male” (opens the source at this quote in a new tab)
“79 - 89% White” (opens the source at this quote in a new tab)
“33 - 38% United States” (opens the source at this quote in a new tab)
“Duration of Psoriasis Diagnosis ~19 years” (opens the source at this quote in a new tab)
“Over 40% prior systemic use” (opens the source at this quote in a new tab)
“Approximately 25% prior biologic use” (opens the source at this quote in a new tab)
“Mean BSA of 26%” (opens the source at this quote in a new tab)
Efficacy results
Co-primary and secondary endpoint results of ONWARD1 and ONWARD2 at topline
PASI 90 and PASI 100 response rates by trial at weeks 16 and 24 in ONWARD1 and ONWARD2
PASI, sPGA, and onset of response in ONWARD1 and ONWARD2 in the congress presentation
Scalp psoriasis response (ss-PGA 0/1) at weeks 4 and 24 in ONWARD1 and ONWARD2
Treat-to-target PASI and BSA thresholds in a post hoc analysis of ONWARD1 and ONWARD2
Efficacy by prior biologic exposure or body weight
No evidence found.
Health-related quality of life and patient-reported outcomes
Quality of life (DLQI 0/1) by week 12 in ONWARD1 and ONWARD2 among participants with baseline DLQI of 2 or more
Mean change in worst pruritus NRS by week 12 and by week 16, and timing relative to PASI 90, in ONWARD1 and ONWARD2
Itch endpoints and methods in the ONWARD1 and ONWARD2 itch analysis
Itch response at week 2, itch resolution at week 16, and responses through week 24 in ONWARD1 and ONWARD2
Safety results
Pooled ONWARD1 and ONWARD2 adverse events through weeks 16 and 24
Deaths, MACE, cytopenias, tuberculosis, laboratory findings, serious infections, and malignancies in pooled ONWARD1 and ONWARD2
Tolerability and most common adverse events in ONWARD1 and ONWARD2 through week 24
Similar adverse event frequency and severity between ONWARD1 and ONWARD2
Herpes zoster and creatine phosphokinase elevations
No evidence found.
Study limitations
Summary
- ONWARD1 results are available from company press releases, a company webcast presentation, and congress materials (Blauvelt et al., Hawkes et al., Ehst et al.). The ClinicalTrials.gov record reads “No Results Posted” and records a certification/extension first submitted on 2026-08-06.
- Placebo control lasted 16 weeks, after which placebo participants rolled over to envudeucitinib; the week 24 PASI results compare envudeucitinib with apremilast alone.
- The report holds no participant disposition by arm, no efficacy by prior biologic exposure or body weight, and no herpes zoster or creatine phosphokinase data. Safety, itch, and DLQI results are reported only for ONWARD1 and ONWARD2 pooled.
- The sources differ on itch: the congress presentation places the mean decrease of more than 4 points in worst pruritus NRS by week 12 and a press release by week 16; at week 16, NRS 0 is reported as over one-third (itch poster) and about 40% (press release), and NRS 0/1 as more than half and approximately 60%.
- Prior treatment is reported on different measures: prior systemic treatment by arm in 221 (48.1%), 113 (49.1%), and 107 (48.0%) participants (congress presentation), and, averaged across both trials, “Over 40% prior systemic use” and approximately 25% prior biologic use (webcast presentation). The report holds no prior biologic use by arm.
- The itch analysis reports nominal P-values, and the PASI and BSA treat-to-target thresholds were calculated post hoc.
- Eligibility excluded participants with lack of clinical response to a TYK2, IL-12, or IL-23 targeted treatment and those with recent or recurrent herpes zoster or herpes simplex infection.
- The webcast presentation lists Belgium among the countries of study ESK-001-016, and the ClinicalTrials.gov API record for NCT06586112 lists Belgium as a removed location country.
ONWARD2
Objective
Objective in the brief title of the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Study start (actual) | “2024-08-20” |
| Primary completion (actual) | “2025-09-23” |
| Study completion (actual) | “2025-12-18” |
| First submitted | “2024-09-07” |
| Last update posted | “2026-10-28” |
Completion dates estimated at registration, September 2024, superseded in June 2025
| Field | Quoted record |
|---|---|
| Primary completion | “2026-05 [Estimated]” |
| Study completion | “2026-06 [Estimated]” |
Results posting status and certification date in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Results | “No Results Posted” |
| Certification/extension first submitted | “2026-08-06” |
Countries of trial sites in the ClinicalTrials.gov record
| Country | First site listed for the country in the record |
|---|---|
| United States | “Birmingham, Alabama, United States, 35203” |
| Austria | “Vienna, Austria, 1220” |
| Canada | “Calgary, Alberta, Canada, T3E 0B2” |
| Estonia | “Tallinn, Estonia, 10128” |
| France | “Nice, France, 06000” |
| Germany | “Berlin, Germany, 10789” |
| Hungary | “Budapest, Hungary, 1152” |
| Israel | “Ramat Gan, Israel, 526200” |
| Latvia | “Riga, Latvia, LV1001” |
| Poland | “Katowice, Poland, 40-568” |
| Puerto Rico | “Caguas, Puerto Rico, 00725” |
| Spain | “Alicante, Spain, 3010” |
Countries listed for ESK-001-017 in the topline webcast presentation
Study design
Design in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Age and sex | “Males or females, age ≥18 years” |
| Disease duration | “Diagnosis of plaque psoriasis for ≥6 months” |
| Body surface area | “Plaques covering ≥10% of BSA” |
| PASI | “PASI ≥12” |
| sPGA | “sPGA ≥3” |
| Contraception | “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception” |
Exclusion criteria on psoriasis type, associated conditions, and pregnancy in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Psoriasis type | “Nonplaque psoriasis or other inflammatory skin conditions” |
| Associated immune-mediated conditions | “Immune-mediated conditions commonly associated with psoriasis (eg inflammatory bowel disease). Patients with psoriatic arthritis may participate” |
| Pregnancy | “Pregnant, lactating, or planning to get pregnant during the study” |
Washout periods and prior treatment response in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Topical therapy | “Topical within 2 weeks” |
| Phototherapy or systemic therapy | “Phototherapy or any systemic treatments within 4 weeks” |
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic agent targeted to IL-12 or IL-23 within 6 months, oral IL-12 or IL-23 or TNFα inhibitor within 2 months, or IL-17 within 4 months” |
| Systemic immunosuppressants | “Systemic immunosuppressants or immunomodulatory drugs within 4 weeks” |
| B-cell and T-cell modulators | “Modulators of B cells within 6 months, or T cells within 3 months” |
| JAK and TYK2 inhibitors | “JAK inhibitors or TYK2 inhibitors within 4 weeks” |
| PDE4 inhibitors | “PDE4 inhibitor within 2 months” |
| Investigational agents | “Any investigational agent, within 30 days or 5 half-lives or is currently enrolled in an investigational study” |
| Prior treatment response | “Lack of clinical response to a TYK2, IL-12, or IL-23 targeted psoriasis treatment” |
Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in October 2024
| Criterion | Quoted record |
|---|---|
| Biologic, oral IL-12 or IL-23, TNFα, and IL-17 agents | “Any biologic or oral agent targeted to IL-12 or IL-23 within 6 months or any TNFα inhibitor within 2 months or IL-17 within 4 months” |
Cardiac, infection, laboratory, and corticosteroid exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
| Arm | Quoted record |
|---|---|
| Experimental: ESK-001 | “ESK-001 administered as an oral tablet” |
| Placebo comparator | “Matching oral placebo” |
| Active comparator: apremilast | “Apremilast administered as an oral capsule” |
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Primary outcome in the ClinicalTrials.gov record
Secondary outcomes in the ClinicalTrials.gov record
Regulatory guidance on the clinical meaning of PASI 75 response and on global assessment scales
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Planned enrollment at registration
| Field | Quoted record |
|---|---|
| Enrollment | “840 [Estimated]” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD2
| Characteristic | Envudeucitinib 40 mg BID, n = 433 | Placebo, n = 211 | Apremilast 30 mg BID, n = 215 |
|---|---|---|---|
| Age, years, mean (SD) | “48.3 (13.1)” | “49.5 (13.3)” | “48.0 (12.8)” |
| Age group, ≥65 years, n (%) | “51 (11.8)” | “28 (13.3)” | “20 (9.3)” |
| Sex, male, n (%) | “283 (65.4)” | “135 (64.0)” | “135 (62.8)” |
| Race, White, n (%) | “388 (89.6)” | “181 (85.8)” | “193 (89.8)” |
| Race, Asian, n (%) | “10 (2.3)” | “10 (4.7)” | “7 (3.3)” |
| Race, other, n (%) | “35 (8.1)” | “20 (9.5)” | “15 (7.0)” |
| Weight, kg, mean (SD) | “92.3 (23.8)” | “91.1 (23.1)” | “90.8 (19.9)” |
| BMI, kg/m2, mean (SD) | “31.2 (7.8)” | “31.1 (7.3)” | “30.9 (5.9)” |
| Duration of disease, years, mean (SD) | “19.0 (13.5)” | “20.2 (14.5)” | “18.7 (14.5)” |
| PASI, mean (SD) | “20.6 (8.3)” | “21.8 (9.0)” | “20.4 (8.4)” |
| sPGA of 4, n (%) | “131 (30.3)” | “70 (33.2)” | “53 (24.7)” |
| BSA % affected, mean (SD) | “25.2 (14.7)” | “27.3 (16.7)” | “25.8 (14.1)” |
| DLQI, mean (SD) | “10.8 (7.0)” | “10.8 (6.8)” | “9.7 (7.1)” |
| Worst pruritus NRS, mean (SD) | “6.4 (2.6)” | “6.4 (2.4)” | “6.0 (2.7)” |
| Prior systemic psoriasis treatment, n (%) | “213 (49.2)” | “105 (49.8)” | “102 (47.4)” |
Baseline itch and scalp involvement by arm in ONWARD2
| Characteristic | Envudeucitinib 40 mg BID, N = 433 | Placebo, N = 211 | Apremilast 30 mg BID, N = 215 |
|---|---|---|---|
| Worst pruritus NRS ≥1, n (%) | “400 (92.4)” | “200 (94.8)” | “199 (92.6)” |
| Worst pruritus NRS ≥4, n (%) | “345 (79.7)” | “180 (85.3)” | “170 (79.1)” |
| ss-PGA ≥3, n | “285” | “140” | “134” |
| Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%) | “231 (81.1)” | “122 (87.1)” | “108 (80.6)” |
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- ONWARD2-specific results are limited to baseline characteristics and PASI 75, PASI 90, and PASI 100 rates at weeks 16 and 24 in one congress presentation. The report holds no description of the ONWARD2 analysis sets, participant disposition, patient-reported outcomes, or safety for ONWARD2 alone, and no ONWARD2 sPGA 0/1 rate.
- The ClinicalTrials.gov record gives an actual enrollment of 862 participants; the congress presentation gives arm sizes of 433, 211, and 215.
- The ClinicalTrials.gov record reads “No Results Posted”, with a certification/extension first submitted on 2026-08-06.
- Asian participants made up 10 (2.3%), 10 (4.7%), and 7 (3.3%) of the envudeucitinib, placebo, and apremilast arms, and White participants 388 (89.6%), 181 (85.8%), and 193 (89.8%).
- Baseline sPGA of 4 was recorded in 131 (30.3%), 70 (33.2%), and 53 (24.7%) participants of the envudeucitinib, placebo, and apremilast arms, and mean baseline PASI was 20.6, 21.8, and 20.4.
ONWARD3
Objective
Objective and scientific questions in the ClinicalTrials.gov record
Location and study date
Study start, completion, and record dates in the ClinicalTrials.gov record
“Study Start (Actual) 2025-01-08” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-11” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2028-11” (opens the source at this quote in a new tab)
“First Posted 2025-02-26” (opens the source at this quote in a new tab)
Recruitment status and last update in the ClinicalTrials.gov record
Countries of trial sites in the ClinicalTrials.gov record
| Country | A site listed for the country in the record |
|---|---|
| United States | “Chandler, Arizona, United States, 85224” |
| Australia | “Campbelltown, South Australia, Australia, 5074” |
| Bulgaria | “Pleven, Bulgaria, 5800” |
| Canada | “Edmonton, Alberta, Canada, T6H 4J8” |
| Czechia | “Brno, Czechia, 602 00” |
| Estonia | “Tartu, Estonia, 50106” |
| France | “Nice, Alpes Maritimes, France, 6000” |
| Germany | “Münster, Germany, NRW 48149” |
| Hungary | “Debrecen, Hungary, 4027” |
| Japan | “Nagoya, Aichi-ken, Japan, 467-8602” |
| Latvia | “Riga, Latvia, LV1013” |
| Poland | “Krakow, Poland, 30-033” |
| Portugal | “Porto, Portugal, 4099-001” |
| Puerto Rico | “San Juan, Puerto Rico, 00917” |
| South Korea | “Seoul, South Korea, 3080” |
| Spain | “Barcelona, Spain, 8041” |
Study design
Design in the ClinicalTrials.gov record
Open-label period, randomized withdrawal, and return to open-label treatment in the ClinicalTrials.gov record
Randomized withdrawal period and planned duration of up to 96 weeks
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Ages, sexes, and healthy volunteers in the ClinicalTrials.gov record
Eligibility to enter ONWARD3 after week 24 of ONWARD1 or ONWARD2
Treatment
Arms and interventions in the ClinicalTrials.gov record
Open-label envudeucitinib 40 mg twice daily for 24 weeks regardless of parent-study treatment
Total envudeucitinib exposure by parent-study arm at week 48
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary outcome in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary outcome measure | “To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study” |
| Measure description and time frame | “Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Approximately 4 years” |
Secondary outcomes in the ClinicalTrials.gov record
Regulatory guidance on the size of the safety database for long-term treatment of non-life-threatening conditions
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the ClinicalTrials.gov record
Participants who entered ONWARD3 from ONWARD1 or ONWARD2, all entrants
Participants entering ONWARD3 by parent-study arm in the congress poster
Description of analysis sets
Non-responder imputation analysis set of 773 participants from the envudeucitinib arms
Maintenance-of-response populations, restricted subgroups, imputation, and confidence intervals in the congress poster
Results
Participant disposition
Enrollment of participants who completed week 24 of ONWARD1 or ONWARD2 and consented
Baseline characteristics
Baseline characteristics at ONWARD3 entry by parent-study arm
| Characteristic | Envudeucitinib then envudeucitinib (n = 773) | Placebo then envudeucitinib (n = 367) | Apremilast then envudeucitinib (n = 369) |
|---|---|---|---|
| Envudeucitinib exposure at start of ONWARD3, weeks | “24” | “8” | “0” |
| Age, years, mean (SD) | “49.6 (13.2)” | “50.6 (13.3)” | “49.1 (12.4)” |
| Duration of disease, years, mean (SD) | “20.2 (13.5)” | “20.1 (13.8)” | “19.0 (13.0)” |
| Prior systemic psoriasis treatment, n (%) | “395 (51.1)” | “185 (50.4)” | “186 (50.4)” |
| PASI, mean (SD) | “1.9 (3.6)” | “4.5 (5.5)” | “6.7 (7.0)” |
| ss-PGA ≥3, n (%) | “18 (2.3)” | “21 (5.7)” | “58 (15.7)” |
| BSA % affected, mean (SD) | “3.8 (7.7)” | “9.4 (12.3)” | “10.7 (13.2)” |
| Worst pruritus NRS score, mean (SD) | “1.3 (1.9)” | “2.0 (2.3)” | “3.1 (2.8)” |
| DLQI, mean (SD) | “1.8 (3.1)” | “2.9 (3.8)” | “4.0 (4.9)” |
Demographics at ONWARD3 entry compared with the parent-trial population
Efficacy results
Week 48 PASI 90 and PASI 100 and maintenance among entry responders, NRI analysis of 773 participants
Week 48 PASI and sPGA responses with continuous envudeucitinib in the congress poster
Maintenance of skin and scalp response at 48 weeks among ONWARD1 and ONWARD2 responders
| Endpoint | Achieved response at the end of ONWARD1 and 2, n | Maintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI) |
|---|---|---|
| PASI 75 | “678” | “89.8 (87.3, 92.0)” |
| PASI 90 | “575” | “89.4 (86.6, 91.8)” |
| sPGA-0/1 | “584” | “87.5 (84.5, 90.1)” |
| PASI 100 | “357” | “80.1 (75.6, 84.1)” |
| sPGA-0 | “365” | “79.5 (74.9, 83.5)” |
| ss-PGA-0/1, among patients with parent baseline ss-PGA ≥3 | “418” | “89.5 (86.1, 92.2)” |
Scalp clearance at 48 weeks and response after crossover from placebo or apremilast
Integrated NRI analysis of 890 participants originally randomized to envudeucitinib across ONWARD1, ONWARD2, and ONWARD3
Health-related quality of life and patient-reported outcomes
Itch and DLQI at 48 weeks, NRI analysis of 773 participants from the envudeucitinib arms
Maintenance of itch and DLQI response at 48 weeks among ONWARD1 and ONWARD2 responders
| Endpoint | Achieved response at the end of ONWARD1 and 2, n | Maintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI) |
|---|---|---|
| At least 4-point improvement from parent baseline in NRS worst pruritus, among patients with parent baseline NRS worst score ≥4 | “509” | “86.2 (82.9, 89.1)” |
| DLQI-0/1, among patients with parent baseline DLQI ≥2 | “497” | “86.3 (83.0, 89.2)” |
Itch and quality-of-life conclusions of the congress poster
Safety results
Adverse events with exposure-adjusted incidence rates by parent-study arm through week 48
| Event | Envudeucitinib then envudeucitinib (n = 773), n (%) | EAIR | Placebo then envudeucitinib (n = 367), n (%) | EAIR | Apremilast then envudeucitinib (n = 369), n (%) | EAIR |
|---|---|---|---|---|---|---|
| At least 1 TEAE | “521 (67.4)” | “177.9” | “253 (68.9)” | “185.4” | “268 (72.6)” | “219.2” |
| At least 1 SAE | “25 (3.2)” | “4.7” | “16 (4.4)” | “6.3” | “9 (2.4)” | “3.6” |
| TEAEs grade ≥3 | “45 (5.8)” | “8.6” | “31 (8.4)” | “12.5” | “16 (4.3)” | “6.5” |
| TEAEs leading to discontinuation | “23 (3.0)” | “4.3” | “11 (3.0)” | “4.2” | “25 (6.8)” | “10.1” |
| Related TEAEs | “104 (13.5)” | “21” | “52 (14.2)” | “21.7” | “82 (22.2)” | “37.9” |
| Nasopharyngitis | “109 (14.1)” | “22.2” | “67 (18.3)” | “28.8” | “44 (11.9)” | “19” |
| Upper respiratory tract infection | “92 (11.9)” | “18.4” | “44 (12.0)” | “18.1” | “44 (11.9)” | “18.7” |
| Influenza | “34 (4.4)” | “6.5” | “19 (5.2)” | “7.5” | “17 (4.6)” | “6.9” |
| Urinary tract infection | “37 (4.8)” | “7.1” | “9 (2.5)” | “3.5” | “13 (3.5)” | “5.3” |
| Acne | “14 (1.8)” | “2.6” | “9 (2.5)” | “3.5” | “18 (4.9)” | “7.5” |
Patient-years of exposure, exposure basis of the incidence rates, deaths, MACE, laboratory abnormalities, malignancies, and tuberculosis
Safety compared with ONWARD1 and ONWARD2 in the topline release
Safety with long-term exposure in the Fall Clinical release
Study limitations
Summary
- Results of the randomized treatment withdrawal period, which began after 24 weeks for the first 200 participants, are “data not reported” in the congress poster.
- All participants received open-label envudeucitinib during the first 24 weeks, with no concurrent control group; regulatory guidance states that the absence of a concurrent control group makes it more difficult to assess the causality relationship between adverse events and the drug.
- Entry required completion of week 24 of a parent trial, consent, and acceptable safety and tolerability of the drug in the parent study. The maintenance analyses are restricted to participants who had a response at entry, and the poster states that the analyses are descriptive.
- Envudeucitinib exposure at week 48 differed by parent-study arm (48, 32, and 24 weeks), and the exposure-adjusted incidence rates are based on exposure in ONWARD3 only.
- Week 48 PASI 90 and PASI 100 rates come from two analyses: a non-responder imputation analysis of 773 entrants (75% and 54%) and an integrated non-responder imputation analysis of 890 participants originally randomized to envudeucitinib (66% and 47%).
- Enrollment is reported as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 by parent-study arm (poster).
- The poster describes malignancies and serious infections as occurring at rates consistent with expected background rates without giving counts, and the report holds no ONWARD3 participant disposition beyond study entry.
- The study is ongoing, with primary completion estimated for 2028-11.
Randomized withdrawal period results not reported in the congress poster
Regulatory guidance on causality assessment in studies without a concurrent control group
STRIDE
Objective
Objective in the published article
Main and secondary objectives in the EU Clinical Trials Register
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2022-09-27” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2023-06-29” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2023-07-25” (opens the source at this quote in a new tab)
“First Posted 2022-10-31” (opens the source at this quote in a new tab)
“Results First Posted 2024-07-23” (opens the source at this quote in a new tab)
Number of sites in the published article, the ClinicalTrials.gov record, and the protocol
Countries of trial sites in the ClinicalTrials.gov record
| Country | First site listed for the country in the record |
|---|---|
| United States | “Birmingham, Alabama, United States, 35205” |
| Canada | “Edmonton, Alberta, Canada, T6G 1C3” |
| Czechia | “Nový Jičín, Czechia, 741 01” |
Planned regions, planned sites, authorization dates, and end date in the EU Clinical Trials Register
“E.8.5.1 Number of sites anticipated in the EEA 15” (opens the source at this quote in a new tab)
“Date of Competent Authority Decision 2023-01-30” (opens the source at this quote in a new tab)
“Date of Ethics Committee Opinion 2023-02-07” (opens the source at this quote in a new tab)
“Date of the global end of the trial 2023-07-25” (opens the source at this quote in a new tab)
Study design
Randomized, double-blinded, placebo-controlled 16-week design with stratified randomization in the published article
Design in the ClinicalTrials.gov record
| Design field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |
Design fields in the EU Clinical Trials Register
“E.7.2 Therapeutic exploratory (Phase II) Yes” (opens the source at this quote in a new tab)
“E.8.1.4 Double blind Yes” (opens the source at this quote in a new tab)
“E.8.1.5 Parallel group No” (opens the source at this quote in a new tab)
“E.8.2.4 Number of treatment arms in the trial 6” (opens the source at this quote in a new tab)
“E.8.7 Trial has a data monitoring committee Yes” (opens the source at this quote in a new tab)
Study duration and safety monitoring committee in the protocol
Eligibility criteria
Inclusion criteria in the protocol
Exclusion criteria on psoriasis type, associated conditions, psoriatic arthritis, and pregnancy in the protocol
Exclusion criteria on prior treatment washout and lack of response to biologic therapies in the protocol
Exclusion criteria on QTcF, cardiovascular disease, infections, and laboratory values in the protocol
“20. Has any of the following lab abnormalities:” (opens the source at this quote in a new tab)
“Absolute neutrophil count <1.5 X 10^9/L” (opens the source at this quote in a new tab)
“Hemoglobin <9 g/dL” (opens the source at this quote in a new tab)
“AST/ALT ≥2 x upper limit of normal (ULN)” (opens the source at this quote in a new tab)
“Albumin <3 g/dL” (opens the source at this quote in a new tab)
Exclusion criteria on corticosteroid-requiring conditions, malignancy, live vaccines, surgery, and mental illness in the protocol
Body mass index added to the weight criterion in the EU Clinical Trials Register
Eligibility criteria summarized in the supplementary material of the published article
Treatment
Dose groups, randomization, administration, and placebo matching in the published article
Arms and tablet regimens in the ClinicalTrials.gov results
| Arm | Arm description in the results |
|---|---|
| ESK-001 10 mg QD | “ESK-001 10mg tablet once a day” |
| ESK-001 20 mg QD | “ESK-001 20mg tablet once a day” |
| ESK-001 40 mg QD | “ESK-001 40mg tablet once a day” |
| ESK-001 20 mg BID | “ESK-001 20mg tablet twice a day” |
| ESK-001 40 mg BID | “ESK-001 40mg tablet twice a day” |
| Placebo | “Placebo tablet” |
Randomization ratio across five dose levels and placebo in the protocol
Study outcomes
Rationale for using PASI 75 response as the primary endpoint
Primary, secondary, and exploratory efficacy end points in the published article
Safety and pharmacokinetic outcomes in the published article
Primary and secondary outcome measures in the ClinicalTrials.gov record
Pharmacokinetic outcome measures at registration, October 2022, superseded in June 2024
Primary and secondary end points in the EU Clinical Trials Register
Exploratory end points in the protocol
PASI and sPGA scoring and the timepoint of the PASI-based end points in the protocol
Responder definitions for DLQI and pruritus NRS in the statistical analysis plan
Regulatory guidance on dose-finding designs and on the duration needed to show short-term efficacy
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the published article
Planned enrollment and sample size assumptions in the protocol
Estimated enrollment at registration in the ClinicalTrials.gov record
Actual enrollment in the ClinicalTrials.gov record
Participants per arm in the intent-to-treat, modified intent-to-treat, and safety analysis sets of the published article
| Analysis set (table) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Intent-to-treat (Table I) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 40)” | “(N = 39)” | “(N = 39)” |
| Modified intent-to-treat (Table II) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |
| Safety (Table III) | “(N = 38)” | “(N = 36)” | “(N = 36)” | “(N = 39)” | “(N = 39)” | “(N = 39)” |
| Analysis set (table) | Pooled ESK-001 column header |
|---|---|
| Intent-to-treat (Table I) | “ESK-001 pooled (N = 190)” |
| Safety (Table III) | “ESK-001 pooled (N = 189)” |
Description of analysis sets
Efficacy and safety analysis populations, statistical tests, and missing-data handling in the published article
Analysis sets named in the table captions and notes of the published article
Analysis populations, stratification factors, multiplicity, and treatment-emergent period in the statistical analysis plan
Intent-to-treat efficacy analysis planned in the protocol
Analysis population for each outcome measure in the ClinicalTrials.gov results
| Outcome measure | Analysis population description |
|---|---|
| PASI-75 (primary) | “Analysis Population Description All Randomized and Treated Participants” |
| Safety and tolerability | “Analysis Population Description Safety Analysis Set” |
| sPGA response | “Analysis Population Description mITT population” |
| Pharmacokinetics | “Analysis Population Description PK Analysis Set” |
Results
Participant disposition
Randomized, dosed, completed, and discontinued participants in the published article
Participant flow by arm with reasons for not completing in the ClinicalTrials.gov results
| Participant flow, overall study | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Started | “38” | “36” | “36” | “40” | “39” | “39” |
| Completed | “33” | “36” | “30” | “37” | “33” | “35” |
| Not completed | “5” | “0” | “6” | “3” | “6” | “4” |
| Reason: adverse event | “0” | “0” | “2” | “0” | “1” | “1” |
| Reason: discontinued prior to dosing due to the blood sample logistics | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: lost to follow-up | “0” | “0” | “2” | “1” | “1” | “0” |
| Reason: protocol violation | “0” | “0” | “0” | “0” | “2” | “0” |
| Reason: subject can't continue with week 16 visit | “0” | “0” | “1” | “0” | “0” | “0” |
| Reason: terminated from the study due to sponsor requirements | “0” | “0” | “0” | “1” | “0” | “0” |
| Reason: withdrawal by subject | “5” | “0” | “1” | “0” | “2” | “3” |
Baseline characteristics
Demographic and baseline disease characteristics by arm in the intent-to-treat set
Balance across arms and overall prior biologic or JAK inhibitor exposure in the published article
Age categories by arm in the ClinicalTrials.gov results
| Age category, participants | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 40 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 | Total, n = 228 |
|---|---|---|---|---|---|---|---|
| 18 years or younger | “0” | “0” | “0” | “0” | “0” | “0” | “0” |
| Between 18 and 65 years | “35” | “33” | “33” | “35” | “37” | “33” | “206” |
| 65 years or older | “3” | “3” | “3” | “5” | “2” | “6” | “22” |
Efficacy results
PASI 75, PASI 90, PASI 100, sPGA 0/1, sPGA 0, and BSA results at week 12 by dose in the modified intent-to-treat set
Primary end point, dose-dependent response, and key secondary end points in the published article
Maintenance of PASI 75 and PASI 90 responses during the 4 weeks off treatment, and response trajectories at week 12
PASI 75 response rates with 95% confidence intervals in the ClinicalTrials.gov results
| Week 12 outcome | Placebo, n = 38 | ESK-001 10 mg QD, n = 36 | ESK-001 20 mg QD, n = 36 | ESK-001 20 mg BID, n = 39 | ESK-001 40 mg QD, n = 39 | ESK-001 40 mg BID, n = 39 |
|---|---|---|---|---|---|---|
| PASI-75, percentage (95% CI) | “0 (0.0 to 9.3)” | “19.4 (8.2 to 36.0)” | “33.3 (18.6 to 51.0)” | “56.4 (36.6 to 72.2)” | “56.4 (39.6 to 72.2)” | “64.1 (47.2 to 78.8)” |
Plasma ESK-001 concentrations by dose in the ClinicalTrials.gov results
| Plasma ESK-001 concentration, ng/ml | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Mean (SD) | “2.9(10.5)” | “11.9(12.4)” | “33.0(49.9)” | “63.9(44.8)” | “50.7(44.8)” | “174.0(125.0)” |
Dose-proportional pharmacokinetics, exposure-response, and trough coverage of the IC90 in the published article
Blood SIGLEC1 and lesional skin biomarker results in the published article
Exploratory exposure-response analysis and selection of the 40 mg twice-daily dose for phase 3
Health-related quality of life and patient-reported outcomes
DLQI 0/1, DLQI 4-point decrease, and pruritus NRS results at week 12 by dose in the modified intent-to-treat set
| Week 12 patient-reported outcome | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
|---|---|---|---|---|---|---|
| DLQI-0/1, n (%) | “7 (18)” | “10 (28)” | “12 (33)” | “20 (51)” | “19 (48)” | “25 (64)” |
| DLQI-0/1, P value vs placebo | “-” | “.2807” | “.1159” | “.0016” | “.0045” | “<.0001” |
| DLQI-0/1, difference vs placebo, % (95% CI) | “-” | “9 (−10, 29)” | “15 (−5, 35)” | “33 (13, 53)” | “30 (10, 50)” | “46 (26, 65)” |
| DLQI 4-point decrease, n (%) | “7 (19)” | “18 (51)” | “18 (51)” | “25 (64)” | “26 (70)” | “24 (65)” |
| DLQI 4-point decrease, P value vs placebo | “-” | “.0032” | “.0032” | “.0001” | “<.0001” | “<.0001” |
| DLQI 4-point decrease, difference vs placebo, % (95% CI) | “-” | “33 (12, 53)” | “33 (12, 53)” | “45 (26, 65)” | “51 (32, 71)” | “46 (26, 66)” |
| Mean change from baseline in average pruritus NRS (SD) | “−1 (3)” | “−2 (3)” | “−3 (3)” | “−4 (3)” | “−4 (3)” | “−5 (3)” |
| Mean change from baseline in worst pruritus NRS (SD) | “−1 (3)” | “−3 (3)” | “−3 (4)” | “−4 (3)” | “−5 (3)” | “−5 (3)” |
| Average pruritus NRS score <4, n (%) | “11 (29)” | “17 (47)” | “21 (58)” | “27 (69)” | “27 (69)” | “28 (72)” |
| Worst pruritus NRS score <4, n (%) | “10 (26)” | “17 (47)” | “18 (50)” | “26 (67)” | “27 (69)” | “29 (74)” |
DLQI 0/1 and average pruritus NRS improvement with 40 mg twice daily in the published article
Median change in average and worst pruritus NRS at week 12 by dose in the congress poster
| Week 12 pruritus NRS change from baseline, median (IQR) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 |
|---|---|---|---|---|---|---|
| Average pruritus NRS | “0.0 (-3.0, 1.0)” | “-2.0 (-3.0, 0.0)” | “-2.5 (-6.0, 0.0)” | “-3.0 (-5.0, -2.0)” | “-5.0 (-6.0, -3.0)” | “-4.0 (-8.0, -3.0)” |
| Worst pruritus NRS | “-0.5 (-2.0, 1.0)” | “-2.0 (-4.0, -1.0)” | “-2.5 (-5.0, 1.0)” | “-4.0 (-6.0, -1.0)” | “-5.0 (-7.0, -3.0)” | “-5.0 (-7.0, -3.0)” |
DLQI reductions of at least 4, 5, and 6 points with 40 mg twice daily and pruritus NRS of 3 or less in the congress poster
EQ-5D results
No evidence found.
Safety results
Treatment-emergent adverse events by dose in the safety analysis set
| Outcome, n (%) | Placebo, N = 38 | ESK-001 10 mg QD, N = 36 | ESK-001 20 mg QD, N = 36 | ESK-001 20 mg BID, N = 39 | ESK-001 40 mg QD, N = 39 | ESK-001 40 mg BID, N = 39 | ESK-001 pooled, N = 189 |
|---|---|---|---|---|---|---|---|
| TEAEs | “15 (39.5)” | “19 (52.8)” | “14 (38.9)” | “18 (46.2)” | “19 (48.7)” | “25 (64.1)” | “95 (50.3)” |
| TEAEs leading to treatment discontinuation | “0 (0.0)” | “0 (0.0)” | “2 (5.6)” | “0 (0.0)” | “2 (5.1)” | “1 (2.6)” | “5 (2.6)” |
| TEAEs grade 3 or higher | “0 (0.0)” | “3 (8.3)” | “1 (2.8)” | “3 (7.7)” | “3 (7.7)” | “0 (0.0)” | “10 (5.3)” |
| TEAEs related to study drug | “5 (13.2)” | “3 (8.3)” | “3 (8.3)” | “5 (12.8)” | “7 (17.9)” | “9 (23.1)” | “27 (14.3)” |
| Headache | “2 (5.3)” | “0 (0.0)” | “2 (5.6)” | “3 (7.7)” | “4 (10.3)” | “3 (7.7)” | “12 (6.3)” |
| Upper respiratory tract infection | “0 (0.0)” | “2 (5.6)” | “2 (5.6)” | “1 (2.6)” | “2 (5.1)” | “3 (7.7)” | “10 (5.3)” |
| Nasopharyngitis | “3 (7.9)” | “2 (5.6)” | “0 (0.0)” | “1 (2.6)” | “1 (2.6)” | “3 (7.7)” | “7 (3.7)” |
| SAEs | “0 (0.0)” | “1 (2.8)” | “0 (0.0)” | “3 (7.7)” | “1 (2.6)” | “0 (0.0)” | “5 (2.6)” |
| Deaths | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
Overall tolerability, common adverse events, and absence of tuberculosis, herpes zoster, opportunistic infections, and oral ulcers in the published article
Serious adverse events by arm, with the gastrointestinal event in the 20 mg twice-daily arm reported as enterocolitis, enteritis, or colitis and enteritis
| Serious adverse event, affected / at risk (%) | Placebo | ESK-001 10 mg QD | ESK-001 20 mg QD | ESK-001 20 mg BID | ESK-001 40 mg QD | ESK-001 40 mg BID |
|---|---|---|---|---|---|---|
| Total | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “3/39 (7.69%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
| Coronary artery occlusion | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Colitis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Enteritis | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Lower limb fracture | “0/38 (0.00%)” | “1/36 (2.78%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Tibia fracture | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” | “0/39 (0.00%)” |
| Dermatitis contact | “0/38 (0.00%)” | “0/36 (0.00%)” | “0/36 (0.00%)” | “0/39 (0.00%)” | “1/39 (2.56%)” | “0/39 (0.00%)” |
Other adverse events reported in at least 5% of participants in any arm in the ClinicalTrials.gov results
Absence of dose-dependent safety signals and of JAK inhibitor-associated adverse events in the discussion of the published article
Absence of MACE, serious infections, treatment-related thromboses, and laboratory or ECG trends in the congress presentation
Study limitations
Summary
- The authors cite the small sample size per treatment group and the 16-week study duration, and the exclusion of participants who were previously nonresponders to IL-17, IL-12, or IL-23 targeted therapies. The protocol also excluded participants with lack of response to 2 or more biologic therapies.
- The primary endpoint was assessed at week 12, when, according to the authors, response trajectories suggested maximal efficacy had not yet been achieved.
- The statistical analysis plan states that no adjustments for multiplicity were performed.
- The analysis population for efficacy differs by source: the protocol planned intent-to-treat analyses, the article used the modified intent-to-treat population, and the ClinicalTrials.gov results describe the PASI 75 population as all randomized and treated participants. The 20 mg BID arm has 40 participants in the intent-to-treat set and 39 in the modified intent-to-treat and safety sets.
- The number of sites is 30 in the article, 53 in the ClinicalTrials.gov record, and approximately 65 planned in the protocol.
- The serious gastrointestinal event in the 20 mg BID arm is reported as enterocolitis (article table footnote), enteritis of unknown etiology (article text), colitis and enteritis as separate terms (ClinicalTrials.gov results), and colitis and enteritis in one subject (congress presentation).
- The article reports 5 participants (2.6%) discontinuing envudeucitinib due to an AE; the ClinicalTrials.gov participant flow lists an adverse event as the reason for not completing the study for 2 (20 mg QD), 1 (40 mg QD), and 1 (40 mg BID) participants.
- The DLQI decrease of at least 4 points with 40 mg BID is 65% in the article and 62% in the patient-reported outcomes poster.
- Acne and folliculitis rates are cited as data on file, skin biopsies were optional and collected from approximately 5 to 12 participants per dose group, and the report holds no EQ-5D results.
Limitations stated by the authors: sample size, duration, and exclusion of prior nonresponders to IL-17, IL-12, or IL-23 therapies
STRIDE open-label extension
Objective
Purpose of the open-label extension in the ClinicalTrials.gov record
Location and study date
Study start, completion, and record dates in the ClinicalTrials.gov record
“Study Start (Actual) 2023-01-17” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-12-01” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-12-31” (opens the source at this quote in a new tab)
“First Posted 2023-02-22” (opens the source at this quote in a new tab)
Completion dates estimated at registration, February 2023, superseded in July 2026
Recruitment status and last update in the ClinicalTrials.gov record
Countries of trial sites in the ClinicalTrials.gov record
| Country | A site listed for the country in the record |
|---|---|
| United States | “Rogers, Arkansas, United States, 72758” |
| Canada | “Surrey, British Columbia, Canada, V3V 0C6” |
North American sites and date of first entry into the open-label extension
Study design
Design in the ClinicalTrials.gov record
Ongoing phase 2 extension with enrollment within 28 days of the STRIDE end-of-study visit
Protocol amendment of January 2024 moving all participants to 40 mg twice daily
Visit and pharmacokinetic sampling schedule
Rollover after the STRIDE week 16 visit and timing of the switch to twice-daily dosing
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Eligibility criteria and prohibited treatments in the supplementary material
Treatment
Allocation to 40 mg once or twice daily by STRIDE dose arm
Numbers allocated to each extension arm from each STRIDE arm
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent and serious adverse events as the primary endpoint
Primary and secondary outcomes in the ClinicalTrials.gov record
Regulatory guidance on one-year exposure in the safety database
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, February 2023, superseded in May 2024
Sample size based on STRIDE completers without a power calculation
Description of analysis sets
Composition of the 40 mg once-daily and overall 40 mg twice-daily groups in the safety and efficacy tables
Analysis sets by arm, ITT population
| Analysis set | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
|---|---|---|---|---|---|
| ITT population | “82” | “83” | “65” | “148” | “165” |
| mITT population | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| Safety analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| PK analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
Post-hoc treat-to-target analyses and mixed model for percent change in PASI
Results
Participant disposition
Rollover from STRIDE: randomized, completing, ineligible, and declining participants
“228 Randomized Phase 2 STRIDE Subjects” (opens the source at this quote in a new tab)
“204 Subjects Completing STRIDE” (opens the source at this quote in a new tab)
“30 Ineligible and not participating in OLE” (opens the source at this quote in a new tab)
“25: OLE Not initiated in Czech Republic” (opens the source at this quote in a new tab)
“5: Did not meet OLE inclusion criteria” (opens the source at this quote in a new tab)
“9 Eligible for OLE but chose not to participate” (opens the source at this quote in a new tab)
Enrollment of 165 participants and one participant not dosed
Participants ongoing and discontinuations at the 52-week data cut-off
Disposition by arm, ITT population
| Disposition | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
|---|---|---|---|---|---|
| Patients ongoing in study, n (%) | “0 (0)” | “66 (79.5)” | “60 (92.3)” | “126 (85.1)” | “126 (76.4)” |
| Patients who switched to 40 mg BID, n (%) | “65 (79.3)” | “-” | “-” | “-” | “65 (39.4)” |
| Discontinued: withdrawal by subject | “6 (7.3)” | “3 (3.6)” | “4 (6.2)” | “7 (4.7)” | “13 (7.9)” |
| Discontinued: lost to follow-up | “3 (3.7)” | “6 (7.2)” | “1 (1.5)” | “7 (4.7)” | “10 (6.1)” |
| Discontinued: inadequate response | “6 (7.3)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “7 (4.2)” |
| Discontinued: adverse event | “1 (1.2)” | “4 (4.8)” | “0 (0)” | “4 (2.7)” | “5 (3.0)” |
| Discontinued: pregnancy | “1 (1.2)” | “0 (0)” | “0 (0)” | “0 (0)” | “1 (0.6)” |
| Discontinued: protocol deviation | “0 (0)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “1 (0.6)” |
| Discontinued: death | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” |
Basis of the disposition counts, data date, and the participant not dosed
Baseline characteristics
Demographics and prior treatment, ITT population
Demographic and baseline characteristics by original dose assignment, ITT population
Efficacy results
Week 52 response rates stated for 40 mg twice daily in the abstract and text, mITT population
Week 28 and week 52 skin responses by original and overall 40 mg twice-daily groups, mITT population, mNRI
| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
|---|---|---|---|
| PASI-75, n (%) | “54 (67.5)” | “62 (77.5)” | “112 (77.8)” |
| PASI-75, 95% CI | “56.1, 77.6” | “66.8, 86.1” | “70.1, 84.3” |
| PASI-90, n (%) | “36 (45.0)” | “49 (61.3)” | “90 (62.5)” |
| PASI-90, 95% CI | “33.8, 56.5” | “49.7, 71.9” | “54.1, 70.4” |
| PASI-100, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| PASI-100, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |
| sPGA-0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “86 (59.7)” |
| sPGA-0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.2, 67.8” |
| sPGA-0, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| sPGA-0, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |
Maintenance of STRIDE week 12 PASI-75 response and continued improvement at week 52, 40 mg twice daily
Improvement in PASI response category from STRIDE week 12 to extension week 52, 40 mg twice daily, mITT population
| Responder status at week 12 of STRIDE | N | Improvement to PASI-75, n (%) | Improvement to PASI-90, n (%) | Improvement to PASI-100, n (%) | Any improvement, n (%) |
|---|---|---|---|---|---|
| Below PASI-75 | “38” | “7 (18.4)” | “8 (21.1)” | “12 (31.6)” | “27 (71.1)” |
| PASI-75 and below PASI-90 | “24” | “----” | “4 (16.7)” | “10 (41.7)” | “14 (58.3)” |
| PASI-90 and below PASI-100 | “11” | “----” | “----” | “4 (36.4)” | “4 (36.4)” |
| Total | “73” | “----” | “----” | “----” | “45 (61.6)” |
Discontinuations among week 52 nonresponders in the original 40 mg twice-daily group
Week 52 compared with extension week 12 in the original 40 mg twice-daily group, mNRI, n = 80
Week 28 PASI and sPGA responses with 40 mg twice daily, mNRI, March 2024 data cut
Treat-to-target thresholds at week 52 with 40 mg twice daily, post-hoc analysis
Health-related quality of life and patient-reported outcomes
DLQI and pruritus responses at week 52 stated in the text, 40 mg twice daily
Week 28 and week 52 patient-reported outcomes by original and overall 40 mg twice-daily groups, mITT population, mNRI
| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
|---|---|---|---|
| DLQI 0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “87 (60.4)” |
| DLQI 0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.9, 68.5” |
| DLQI 4-point decrease, n (%) | “49 (61.3)” | “55 (68.8)” | “103 (71.5)” |
| DLQI 4-point decrease, 95% CI | “49.7, 71.9” | “57.4, 78.7” | “63.4, 78.7” |
| Average pruritus NRS score below 4, n (%) | “54 (67.5)” | “65 (81.3)” | “115 (79.9)” |
| Average pruritus NRS score below 4, 95% CI | “56.1, 77.6” | “71.0, 89.1” | “72.4, 86.1” |
| Worst pruritus NRS score below 4, n (%) | “51 (63.8)” | “63 (78.8)” | “112 (77.8)” |
| Worst pruritus NRS score below 4, 95% CI | “52.2, 74.2” | “68.2, 87.1” | “70.1, 84.3” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, n (%) | “44 (55.0)” | “47 (58.8)” | “89 (61.8)” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, 95% CI | “43.5, 66.2” | “47.2, 69.6” | “53.3, 69.8” |
Itch control and DLQI at week 52 stated in the company release, original 40 mg twice-daily group
Minimal or no impact on quality of life at weeks 12 and 52 with 40 mg twice daily
Safety results
Adverse events with exposure-adjusted incidence rates through week 52, safety analysis population
| Event, n (%) [EAIR] | Original 40 mg QD (N = 82) | Overall 40 mg BID (N = 147) | Overall (N = 164) |
|---|---|---|---|
| Patients with at least 1 TEAE | “50 (61.0) [122.76]” | “73 (49.7) [102.33]” | “108 (65.9) [108.18]” |
| Patients with TEAE leading to study drug discontinuation | “1 (1.2) [1.55]” | “5 (3.4) [4.19]” | “6 (3.7) [3.26]” |
| Patients with TEAE grade 3 or higher | “3 (3.7) [4.66]” | “6 (4.1) [5.12]” | “8 (4.9) [4.42]” |
| Upper respiratory tract infection | “3 (3.7) [4.71]” | “13 (8.8) [11.66]” | “16 (9.8) [9.20]” |
| Nasopharyngitis | “10 (12.2) [16.88]” | “6 (4.1) [5.15]” | “14 (8.5) [8.09]” |
| COVID-19 | “3 (3.7) [4.74]” | “8 (5.4) [6.88]” | “11 (6.7) [6.17]” |
| Headache | “5 (6.1) [8.28]” | “5 (3.4) [4.28]” | “10 (6.1) [5.71]” |
| Patients with at least 1 treatment-emergent SAE | “2 (2.4) [3.10]” | “4 (2.7) [3.39]” | “6 (3.7) [3.29]” |
| Patients with SAEs related to study drug | “2 (2.4) [3.10]” | “2 (1.4) [1.67]” | “4 (2.4) [2.17]” |
| Patients with TEAE leading to death | “0 (0) [-]” | “0 (0) [-]” | “0 (0) [-]” |
Adverse events leading to discontinuation, frequency threshold, and severity of the most frequent events
Overall tolerability, severity, acne, and folliculitis
Comparison of the once-daily and twice-daily arms, including related adverse events
Treatment-related adverse events with exposure-adjusted incidence rates, September 2024 data cut
Laboratory values, lipids, cytopenia, rhabdomyolysis, and tuberculosis
Herpes zoster, electrocardiograms, and thromboembolic events
Study limitations
Summary
- The authors state that this was an open-label study with limited sample size and no placebo or active comparator.
- No formal power calculation was performed; the sample consisted of STRIDE completers who qualified and chose to enroll. The extension was not initiated in the Czech Republic, which made 25 STRIDE completers ineligible, and the study was conducted at North American sites only.
- Dose assignment followed the STRIDE arm for participants from the 10 mg QD and 20 mg QD arms (40 mg QD) and the 20 mg BID and 40 mg BID arms (40 mg BID); participants from the placebo and 40 mg QD arms were allocated to either dose. The ClinicalTrials.gov record lists the allocation as randomized.
- A protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64, so the overall 40 mg BID group (N = 148, intent-to-treat) includes 65 participants who switched from 40 mg QD.
- Efficacy baseline was STRIDE Day 1, and participants entered the extension with a mean PASI of 8.5. Responder analyses used modified nonresponder imputation, carrying the last observation forward for discontinuations other than for AEs or inadequate response.
- Week 52 PASI 100 with 40 mg BID is 39% in the article text, 31 of 80 (38.8%) in the original 40 mg BID group, and 47 of 144 (32.6%) in the overall 40 mg BID group. Itch control in the original 40 mg BID group is reported as “NRS≤4, 81.3%” in a press release and as average pruritus NRS below 4 in 65 participants (81.3%) in the article table.
- Data cutoffs differ: the supplement includes data from 18 November 2024, and a congress poster by Blauvelt et al. displays safety data from the 06 SEP 2024 data cut. The treat-to-target analyses and the analysis of an improvement of at least 4 points in worst pruritus NRS are post hoc.
- The study is ongoing; 126 participants (76.4%) were continuing treatment at the 52-week data cut-off, and study completion is estimated for 2027-12-31.
Open-label design, sample size, and absence of a control group as stated by the authors
ACTRN12621000011886
Objective
Aims of the first-in-human and multiple-dose studies
“The aim of the studies was to assess the safety, tolerability, PK, pharmacodynamics (PD), and the effect of a high‐calorie breakfast of single and multiple oral doses of ESK‐001 in healthy adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-finding purpose of the wide dose range
Location and study date
Study period and site of the first-in-human study in the publication
“This was a first‐in‐human, phase I, single‐center, randomized, double‐blinded, placebo‐controlled, single (SAD) and multiple ascending dose (MAD) study of oral ESK‐001 administration in healthy participants (ACTRN12621000011886), conducted between January 21, 2021 and February 24, 2022 at a facility in Adelaide (Australia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registration, enrollment, and data collection dates in the ANZCTR record
| Field | Quoted record |
|---|---|
| Date submitted | “26/11/2020” |
| Date registered | “11/01/2021” |
| Type of registration | “Prospectively registered” |
| Recruitment status | “Completed” |
| Date of first participant enrolment, anticipated | “29/01/2021” |
| Date of first participant enrolment, actual | “17/02/2021” |
| Date of last participant enrolment, anticipated | “17/11/2021” |
| Date of last participant enrolment, actual | “19/01/2022” |
| Date of last data collection, anticipated | “30/11/2021” |
| Date of last data collection, actual | “4/02/2022” |
| Date last updated | “14/06/2022” |
Recruitment state and principal investigator site in Adelaide, Australia, in the ANZCTR record
| Field | Quoted record |
|---|---|
| Recruitment state(s) | “SA” |
| Principal investigator | “Prof Sepehr Shakib” |
| Principal investigator address | “CMAX Clinical Research Pty Ltd Level 5, 18 a North Terrace Adelaide, SA, 5000 Australia” |
Results documents and data sharing in the ANZCTR record
| Field | Quoted record |
|---|---|
| Will the study consider sharing individual participant data? | “No” |
Study design
Study type, allocation, control, and phase in the ANZCTR record
| Field | Quoted record |
|---|---|
| Health condition(s) studied | “Psoriasis” |
| Study type | “Interventional” |
| Purpose of the study | “Treatment” |
| Allocation to intervention | “Randomised controlled trial” |
| Control group | “Placebo” |
| Phase | “Phase 1” |
Secondary sponsor, funding, and ethics approval in the ANZCTR record
| Field | Quoted record |
|---|---|
| Funding source category | “Commercial sector/Industry” |
| Secondary sponsor name | “Avance Clinical Pty Ltd” |
| Ethics committee name | “Bellberry Human Research Ethics Committee” |
| Ethics approval date | “10/12/2020” |
| Ethics approval number | “2020-11-1116” |
Regulatory framework of the Australian study
“The study adhered to the applicable regulations of the Australian Therapeutic Goods Administration under the Clinical Trial Notification scheme, the principles of the Declaration of Helsinki, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 (R2) Good Clinical Practice – Scientific Guideline, and the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding and randomization procedures
“The Sponsor, Principal Investigator, clinical study personnel, and study participants were blinded to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any analysis of PK and PD data prior to unblinding was performed by the unblinded bioanalytical laboratory and pharmacokineticist at Avance Biometrics who had no responsibility for data monitoring and management in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data were reblinded before being provided to any study personnel who were to remain blind.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization was prepared by unblinded statisticians using SAS Version 9.4 (or higher), provided to pharmacy staff involved in study drug dispensing, and maintained in a restricted access area.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single ascending dose part: confinement, escalation, and 3:1 randomization
“In the SAD part, the screening period from Day −28 to −2 was followed by admission of the participants to the facility from Day −1 to 3 (Day 4 for Cohort 25 mg) with dose administration on Day 1 and final safety assessments on Day 7 ± 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose escalation was based on the safety and PK results of the previous dose cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive a single oral dose of ESK‐001 or placebo (3:1) in fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect cohort: two periods separated by a washout
“Eight participants were allocated to the food effect (FE) cohort and were admitted to the facility from Day −1 to 8, with the first study drug administration on Day 1 (Period 1), followed by a 5‐day washout period and second dose administration on Day 6 (Period 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Final safety assessments occurred on Day 12 ± 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single ascending dose cohorts in the congress poster's design schematic
Eligibility criteria
Age, body mass index, and health criteria in the published report
“Eligible participants included adult men and women, aged 18–55 years (SAD/MAD) or 18–60 years (MD), with a BMI of 18.0–32.0 kg/m2, body weight ≥50 kg (SAD/MAD), and medically healthy as determined by physical examination, vital signs, conventional 12‐lead electrocardiogram (ECG), and routine laboratory parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women were of nonchildbearing potential or had a negative pregnancy test if childbearing potential and were not lactating.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key inclusion criteria and age limits in the ANZCTR record
Key exclusion criteria in the ANZCTR record
Treatment
Liquid formulation and matching placebo
“The active treatment was a liquid formulation of ESK‐001 (Batch number: JR‐C200609006‐FPF20001), while placebo contained the same excipients as the active treatment, with denatonium benzoate (Batch number: R086X0) instead of ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Planned and actual single ascending dose levels and starting dose basis
“Planned dose levels were in the range of 5–150 mg; actual dose levels were 5, 10, 17.5, 25, 50, and 100 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The starting dose was determined based on preclinical data and allometric scaling in accordance with FDA guidance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose escalation was based on the observed safety, pharmacokinetics data, and in vitro TYK2 pharmacodynamic marker levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect cohort dose of 25 mg fasted and after a high-calorie meal
Single ascending dose, food effect, and multiple ascending dose regimens in the ANZCTR record
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Primary and secondary outcomes in the ANZCTR record
Adverse event recording period and adverse events expected with TYK2 inhibitors in the ANZCTR record
Safety assessments in the published report
“Safety assessments included: (1) recording of treatment‐emergent adverse events (TEAEs) including serious TEAEs, TEAEs leading to death, and TEAEs leading to study drug and/or study discontinuation; (2) clinical laboratory parameters; (3) vital signs; (4) body weight (SAD/MAD); (5) ECG parameters; and (6) physical examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic sampling and urine and feces collection in the single ascending dose part
“Blood and urine samples were collected predose and at several timepoints postdose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the SAD part, urine samples were only collected for the Cohort 50 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Feces were also collected in the SAD/MAD study but not analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled in the single and multiple ascending dose parts
Absence of a formal sample size calculation
Description of analysis sets
Safety analysis set
“The safety analysis was based on all randomized participants who received at least 1 dose of the study drug and had at least 1 postdose safety assessment, and was conducted by actual treatment received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose proportionality and food effect analyses
“Dose proportionality was assessed using the power model with linear regression method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The FE was determined by comparing the PK of ESK‐001 in fed and fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Natural log‐transformed maximum concentration (C max) and area under curve (AUC) were analyzed by an analysis of variance (ANOVA) using PROC MIXED in SAS with treatment, period, and sequence as a fixed effect and participant as a random effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Incomplete recruitment of two cohorts during the COVID-19 pandemic
Withdrawal of two food effect cohort participants
“Two participants of the FE cohort discontinued the study drug and study due to TEAEs (see Safety and Tolerability results), that were indicative of a possible COVID‐19 infection, requiring isolation and withdrawal from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Race, ethnicity, sex, and body mass index in the single ascending dose part
“Most participants were white, not Hispanic or Latin, male in the cohorts receiving ESK‐001 and female in the pooled placebo cohorts (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean BMI ranged from 21.7 to 26.6 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Absorption, half-life, dose proportionality, and volume of distribution after single doses
“Following single doses of 5 to 100 mg, ESK‐001 was rapidly absorbed with a median time to C max (T max) of 0.8–1.1 h and showed linear PK characteristics with low variability across the dose cohorts (Figure 3a, Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean terminal half‐life (t ½) was 7.5– 9.3 h and was consistent across the different dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The AUC from time zero to infinite time (AUC0–inf) and C max increased in a near dose‐proportional manner at doses of 5– 100 mg, and C max plateaued at doses of 50 mg and above, indicating that absorption of ESK‐001 was slowing down at higher doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean apparent distribution volume during the terminal phase (Vz/F) was high, ranging from 103 to 186 L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A similar PK profile was observed following multiple doses in the MAD part (Figure S2, Table S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma pharmacokinetic parameters by single ascending dose and food effect cohort
Urinary excretion of unchanged drug after a single 50 mg dose and multiple doses
“Urinary excretion of ESK‐001 was minimal following single 50 mg and multiple‐dose administration of ESK‐001, with mean percentage of unchanged drug excreted (%Fe) (coefficient of variation [CV%]) ranging from 0.42% (58%) to 0.93% (49%), and geometric mean renal clearance of unchanged drug from the plasma (CLr) (CV%) ranging from 53.4 (77%) to 101 mL/h (53%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Food effect with the liquid formulation at 25 mg
“The AUC0–inf was similar under fed and fasted dose administration of 25 mg ESK‐001 (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, C max was reduced by ~50% and median T max increased from 0.75 h to 4 h under fed conditions, indicating that food slowed the absorption of ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although food slowed the absorption of ESK‐001, data suggest that ESK‐001 may be administered with or without food, as the bioavailability (AUC0–inf) of ESK‐001 was similar under fed and fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamic results of the multiple ascending dose part
“PD parameters were also assessed in the MAD part of the SAD/MAD study but are not discussed in this article.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similar results on biomarker changes were observed in the MAD part of the SAD/MAD study (data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by single ascending dose cohort
Incidence, severity, relatedness, and discontinuations in the single ascending dose part
“In the SAD part, 37 (69.8%) participants experienced 105 TEAEs; 32 (78.0%) participants receiving ESK‐001 experienced 96 TEAEs and 5 (41.6%) participants receiving placebo experienced 9 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most TEAEs (94.3%) were mild in severity and a few moderate in severity (all following administration of ESK‐001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no dose‐related trends in the incidence and severity of TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants in the FE cohort discontinued the study drug and study due to TEAEs indicative of a possible COVID‐19 infection, one after 1 dose (fed) in Period 1 due to upper respiratory tract infection, and one after 1 dose (fasted) in Period 1 due to sinus congestion, cough, and sneezing, all mild in severity and not related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAE (reported in ≥30% of the participants in any group) by preferred term was a headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the cohorts receiving ESK‐001, most TEAEs were considered related to the study drug by the investigator; 25 (61.0%) participants receiving ESK‐001 experienced 55 TEAEs considered related to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two (16.6%) participants receiving placebo experienced 3 TEAEs considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no apparent treatment or dose‐related trends in the clinical laboratory results and no TEAEs arising from abnormalities in clinical laboratory results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety in the multiple ascending dose part
“For the MAD part, a similar safety profile as for the SAD part was observed (Table S6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant receiving ESK‐001 (Cohort 10 mg q.d fasted) discontinued the study drug and study after 1 dose due to TEAEs of nausea and vomiting, both mild in severity and both considered related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths, serious and severe events, vital signs, and electrocardiograms across both phase 1 studies
“Overall, there were no deaths, serious TEAEs, nor severe TEAEs reported in either the SAD/MAD or MD studies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No clinically relevant changes were observed in vital signs, ECGs, and physical examination findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, there were no MACE, malignancies, venous thromboembolisms, or adverse trends in laboratory parameters observed, which are commonly associated with non‐selective JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac conduction and concentration-QTc analysis
“Per cardiodynamic analyses, ESK‐001 had no clinically relevant effect on cardiac conduction (i.e., the PR and QRS intervals).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the concentration‐QTc analysis, an effect on the placebo‐corrected change from baseline QTcF (QT interval corrected using Fridericia's method) exceeding 10 ms can be excluded within the observed range of ESK‐001 plasma concentrations up to ~ 1000 ng/mL (data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
- The authors note that the study provided short-term exposure data, so chronic effects such as cumulative toxicity were not captured.
- The multiple ascending dose part is reported in supplementary figures and tables, and its biomarker results and the concentration-QTc results are reported as data not shown.
- Participants were healthy adults dosed with a liquid formulation of ESK-001.
- Because of the COVID-19 pandemic, the 17.5 mg and 100 mg cohorts could not be filled to the planned 8 participants (N = 4 and N = 5 in the pharmacokinetic table), and 2 food effect cohort participants withdrew with TEAEs indicative of a possible COVID-19 infection.
- The article and the registry differ: the article reports 91 participants enrolled and a study conducted between January 21, 2021 and February 24, 2022; the ANZCTR record gives a final sample size of 87, a first enrolment on 17/02/2021, and a last data collection on 4/02/2022.
- No formal sample size calculation was performed. Feces were collected but not analyzed, and urine was collected only for the 50 mg cohort of the single ascending dose part.
- The ANZCTR record states that no documents have been uploaded by study researchers and answers No to whether the study will consider sharing individual participant data.
Short-term exposure in both phase 1 studies
“Some study limitations should be taken into consideration, including that both the SAD/MAD study and the MD study provided short‐term exposure data, and hence, chronic effects (eg, cumulative toxicity) were not captured (as mentioned above).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, long‐term safety studies are needed to further evaluate the safety of ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiple ascending dose part reported only in the supplement
“As this article focuses on the tablet formulation, details of the MAD part are not discussed in detail.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study details of the MAD part are described in Appendix S1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESK-001-003
Objective
Pharmacokinetic and pharmacodynamic assessment for dose selection
Location and study date
Study period and single site in Glendale, United States, in the published report
“This was a phase I, single‐center, randomized, double‐blinded (with Sponsor unblinded), placebo‐controlled, parallel‐group, MD study of oral ESK‐001 immediate release tablet administration in healthy participants (NCT05431634), conducted from April 15, 2022 to September 20, 2022 at a facility in Glendale (US).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2022-05-12” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2022-12-01” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2022-12-31” (opens the source at this quote in a new tab)
“First Submitted 2022-06-09” (opens the source at this quote in a new tab)
“First Posted 2022-06-24” (opens the source at this quote in a new tab)
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-003” |
| Conditions | “Safety and Tolerability” |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “Double (ParticipantInvestigator)” |
Blinding, confinement, and 14-day dosing schedule
“The Principal Investigator, clinical study personnel, and study participants were blinded to treatment with the Sponsor unblinded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the screening period from Day −29 to −2, participants were admitted to the facility from Day −1 to 16 for a 14‐day course of the study drug with first dose administration on Day 1, and returned 5–7 days after the last dose for final safety assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization utilized a randomization code and restricted access area maintenance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory framework of the United States study
“The study adhered to the 21 Code of Federal Regulation guideline, the principles of the Declaration of Helsinki, the ICH E6 (R2) Good Clinical Practice – Scientific Guideline, the requirements of national drug and data protection laws, in particular, the Health Insurance Portability and Accountability Act of 1996.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Inclusion: age | “Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit” |
| Inclusion: health status | “Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters” |
| Inclusion: other | “Other inclusions as specified in the protocol” |
| Exclusion: prior exposure | “Participant has a prior exposure to ESK-001” |
| Exclusion: hypersensitivity | “Participant has a history of hypersensitivity to any of the ingredients of ESK-001” |
| Exclusion: other | “Other exclusions as specified in the protocol” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Tablet strengths and matching placebo
“The study products included ESK‐001 30 mg tablet (Batch number: 25089), ESK‐001 10 mg tablet (Batch number: 25087), and matching placebos (30 mg tablet [Batch number: 25206], 10 mg tablet [Batch number: 25204]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Six dose regimens and the basis for dose and fasting conditions
“Doses were 20 mg once daily (q.d.) fasted, 20 mg once every 12 h (Q12) fasted, 40 mg Q12 fasted, 10 mg q.d. fasted, 30 mg Q12 nonfasted, and 60 mg q.d. nonfasted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose levels were determined based on the SAD/MAD study results and relative bioavailability study data of the tablet vs. liquid formulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The fasting requirement was adjusted for the last two cohorts, based on data from the FE cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Pharmacodynamic assessments: pSTAT1 flow cytometry and whole-blood RNA sequencing
“The effect of ESK‐001 on exploratory PD and biomarker parameters was evaluated in the whole blood of healthy participants from the MD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Flow cytometry analysis of pSTAT1 (phosphorylated signal transducer and activator of transcription 1) expression in T cells in IFNα‐stimulated whole blood and RNA sequencing of unstimulated whole blood was performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definitions of percentage pSTAT1 inhibition and the type I interferon and SIGLEC1 signatures
“The percentage inhibition of pSTAT1 was calculated for each participant for each timepoint as the percentage change from baseline (Day 1 predose).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RNA sequencing was performed to analyze type I IFN gene and SIGLEC1 signature, which were defined as the median transcript expression of the Dx Terity panel genes HERC5, RSAD2, IFI27, and IFIT1, and SIGLEC1, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urine collection and pharmacokinetic-pharmacodynamic sampling in the multiple-dose study
“Urine was collected from all MD cohorts but only cohorts 20 mg q.d., 60 mg q.d., and 40 mg Q12 were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Parallel collection of PK samples alongside PD sampling enabled the determination of the ESK‐001 PK/PD relationship.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned cohort size and participants enrolled per cohort
“Participants were randomized to six cohorts (planned cohort size: 8 participants) to receive ESK‐001 or placebo (3:1), with 49 participants (36 for ESK‐001 and 13 for placebo) enrolled per Sponsor's decision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, June 2022, superseded in May 2023
Description of analysis sets
Steady-state assessment and software for pharmacokinetic and statistical analyses
“Plasma ESK‐001 steady state was assessed by calculating the 90% confidence interval (CI) of the slope of the linear regression of loge (concentration at the end of a dose interval [C trough]) vs. time in the MD study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PK analyses were conducted using Phoenix WinNonlin Version 8.3 or higher, and all statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary, North Carolina, USA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Data included in the pharmacokinetic-pharmacodynamic analysis
“All available individual PD TYK2 inhibition data points (across all valid cohorts, doses, and timepoints) with matching PK measurements were included in the assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individual PD results were plotted against their respective exposure (in μM) on a semi‐log scale graph and best‐fit curve (log inhibitor vs. response, four parameters) was generated in GraphPad Prism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per protocol, PD samples were to be collected on Day 14, but for some participants, the PD samples were collected on Day 13.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“N = 6 participants, except for Cohort 30 mg Q12 Day 14 (N = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of placebo participants with unexpected plasma concentrations
Results
Participant disposition
Randomization and discontinuations in the multiple-dose study
“In the MD study, 49 participants were randomized to study treatment (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five participants discontinued the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants discontinued the study drug and study due to TEAEs (see Safety and Tolerability results).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant receiving ESK‐001 (Cohort 20 mg q.d. fasted) discontinued the study drug and study after the sixth dose due to psychotic behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, two participants receiving placebo discontinued the study drug and study due to withdrawal by participant (both for personal reasons, non‐safety‐related); one (Cohort 40 mg Q12 fasted) after the second dose on Day 10, and another (Cohort 30 mg Q12 nonfasted) after the first dose on Day 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Race, ethnicity, sex, and body mass index in the multiple-dose study
“Most participants were white and not Hispanic or Latin (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, sex was balanced between cohorts receiving ESK‐001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean BMI ranged from 24.0 to 26.8 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Absorption, half-life, dose proportionality, steady state, and accumulation with the tablet
“ESK‐001 was rapidly absorbed into the systemic circulation with a median T max of 1.5–3.1 h on Day 1 following a single dose, and 1.1–2.2 h on Day 14 following multiple q.d. or Q12 doses (Figure 3b, Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean t½ after the last dose on Day 14 ranged from 7.6 to 12.4 h across all q.d. or Q12 doses and no trend with dose or dose regimen was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, no trend with dose was observed for geometric mean apparent steady‐state volume of distribution (Vss/F) and mean apparent total plasma clearance (CL/F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After multiple q.d. doses and after the first dose administration of Q12 doses, AUC from time zero to time tau (AUC0–tau) appeared to increase in a dose‐proportional manner (slope estimates [95% CI] were 0.934 [0.62;1.25] and 0.992 [0.49, 1.49], respectively), although 95% CIs were wide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No definitive conclusion could be derived on dose proportionality for q.d. doses on Day 1 and for Q12 doses on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Steady state was achieved by Day 3 following q.d. and Q12 multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following multiple q.d. doses, accumulation ratios (R ac) based on C max and AUC0–tau showed no to minimal accumulation of ESK‐001 (mean R ac C max ranged from 0.71 to 1.41 and mean R ac AUC from 0.80 to 1.39).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following multiple Q12 doses, there was an ~ 2‐fold accumulation of ESK‐001 (mean R ac C max ranged from 1.74 to 2.17 and mean R ac AUC from 1.74 to 2.42).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The C trough levels at the highest ESK‐001 dose of 40 mg Q12 were maintained above the in vitro human whole blood (HWB) 90% pSTAT inhibitory concentration (IC90) threshold (Figure 3c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma pharmacokinetic parameters by multiple-dose cohort on days 1 and 14
“Summary of plasma PK parameters of ESK‐001 following administration of single and multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Urinary excretion of unchanged drug in the multiple-dose study
“Only a small amount of unchanged ESK‐001 was eliminated in urine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean %Fe (CV%) and CLr (CV%) were comparable for Cohort 60 mg q.d. (nonfasted) (0.43% [94.7%] and 63.8 mL/h [66.8%], respectively) and Cohort 40 mg Q12 (fasted) (0.37% [55.8%] and 46 mL/h [115.2%], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to one outlier participant with very high %Fe (45.4%) and CLr (24.3 L/h) compared with the other participants in the same treatment group, the mean %Fe and CLr for the Cohort 20 mg q.d. (fasted) were higher (1.12% [935.9%] and 203.7 mL/h [4430.3%], respectively) than for the Cohorts 60 mg q.d. (nonfasted) and 40 mg Q12 (fasted).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elimination route in the congress poster's summary of the multiple-dose study
Inhibition of IFNα-induced pSTAT1 in T cells by dose
“In the MD study, IFNα‐induced pSTAT1 expression was analyzed in T cells from whole blood as a measure of TYK2 inhibition and confirmed robust pharmacologic activity of ESK‐001 with a clear dose‐dependent effect (Figure 4a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal TYK2 pathway inhibition was achieved within 2–4 h for all doses >10 mg q.d., with dose‐dependent differences observable at later timepoints following the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the highest daily dose of 80 mg (administered as 40 mg Q12), maximal levels of TYK2 inhibition were achieved within 2–4 h and maintained throughout the Q12 dose interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the lowest total daily dose of 10 mg q.d., a partial TYK2 inhibition profile was achieved, with TYK2 inhibition peaking at <50% inhibition within 2–4 h and quickly returning to baseline TYK2 activity with minimal inhibition measured at 12 and 24 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All dose levels returned toward normal TYK2 activity 24–48 h after the last dose on Day 14.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type I interferon gene signature and SIGLEC1 expression
“The mRNA transcriptomics analysis showed clear dose‐dependent inhibition of type I IFN gene signature on Day 14 with full inhibition at higher doses, which was concordant with pSTAT1 functional assay results (4b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, clear dose‐dependent inhibition of expression of SIGLEC1 (sialic acid binding Ig like lectin 1), a novel TYK2‐responsive biomarker, was observed (Figure 4c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Downstream cytokine inhibition in the congress poster
Pharmacokinetic-pharmacodynamic relationship at the highest and lowest doses
“At the highest dose of 40 mg Q12, peak (2–4 h after the last dose) and trough (12 h after the last dose) samples showed maximal TYK2 inhibition, which aligned with PK exposures at or above the in vitro HWB pSTAT IC90 threshold and was maintained throughout the treatment period (Figure 5c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As expected at the lowest dose (10 mg q.d.), ESK‐001 demonstrated only a partial profile of TYK2 inhibition with limited TYK2 inhibition achieved at peak timepoints (2–4 h after the last dose), which was not maintained at trough timepoints (24 h after the last dose) (Figure 5b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESK‐001 demonstrated a strong PK/PD relationship, with high predictability, low variability, and a clear sigmoidal exposure–response relationship with TYK2 inhibition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher levels of drug exposure above the IC90 guide point did not result in additional pharmacological effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose range selected for the STRIDE phase 2 study
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by multiple-dose cohort
Incidence, severity, relatedness, discontinuations, and laboratory findings in the multiple-dose study
“Thirty‐eight (77.6%) participants experienced 91 TEAEs; 27 (75.0%) participants receiving ESK‐001 experienced 72 TEAEs and 11 (84.6%) participants receiving placebo experienced 19 TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most TEAEs (90.1%) were mild in severity; all other TEAEs were moderate in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no dose‐dependent increase in the number of TEAEs or meaningful change in the severity levels observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The frequency of headaches appeared to increase with increasing dose of ESK‐001; however, most headaches (80.8%) were observed to be mild in severity across all dose levels and resolved without sequalae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants discontinued the study drug and study due to TEAEs; one participant receiving ESK‐001 (Cohort 30 mg Q12 nonfasted) due to rash morbilliform (considered study drug‐related), and one receiving placebo (Cohort 60 mg q.d. nonfasted) due to COVID‐19 (considered not study drug‐related); both TEAEs were mild in severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs (reported in ≥30% of the participants in any group) by preferred term were erythema and headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Events of erythema were secondary to skin taping for a sample collection procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen (41.7%) participants receiving ESK‐001 experienced 29 TEAEs considered related to the study drug and 1 (7.7%) participant receiving a placebo experienced a TEAE considered related to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Minor fluctuations occurred in coagulation, clinical chemistry, and urinalysis parameters, but without treatment‐related trends.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants reported an abnormal clinically meaningful laboratory value; one for Strep A2 rapid screen on Day 8, and one for SARS‐CoV‐2 RNA on Day 9.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths, serious events, and adverse events of special interest in the congress poster's safety summary
Study limitations
Summary
- The authors advise caution in interpreting the dose proportionality analysis because of the small number of participants, the limited q.d. and Q12 dose range, and the wide 95% CIs; no definitive conclusion could be derived for q.d. doses on Day 1 and Q12 doses on Day 14.
- Participants were 49 healthy adults (36 envudeucitinib, 13 placebo) treated for 14 days at one site.
- The last two cohorts (30 mg Q12 and 60 mg q.d.) were dosed nonfasted, while the other cohorts were dosed fasted.
- The Sponsor was unblinded, and five placebo participants with unexpected ESK-001 plasma concentrations were excluded at the Sponsor's request.
- Some pharmacodynamic samples were collected on Day 13 instead of Day 14, and urine was analyzed for only 3 of the 6 cohorts, with one outlier participant raising the 20 mg q.d. means.
- Erythema, the most common TEAE with headache, was secondary to skin taping for a sample collection procedure.
- The article describes a parallel-group study conducted from April 15, 2022 to September 20, 2022; the ClinicalTrials.gov record lists sequential assignment, a start on 2022-05-12, and completion on 2022-12-31, and reads “No Results Posted”.
Small sample and limited dose range for the dose proportionality analysis
“Furthermore, in the MD study, the results of statistical analysis of the dose proportionality should be cautiously interpreted in light of the small number of participants included in the analysis, the limited q.d. and Q12 dose range examined, and the wide 95% CI around the estimated slopes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Asian ethnic bridging study
Objective
Primary and secondary objectives
Location and study date
No evidence found.
Study design
Sequential periods and blood sampling in the Japanese and Chinese cohorts
Caucasian reference cohort given the expected therapeutic dose only
Eligibility criteria
Treatment
Fed-state dosing in the Asian cohorts and fasted-state dosing in the Caucasian cohort on day 7 of twice-daily dosing
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Noncompartmental analysis of the parent drug and its main metabolite
Statistical analysis description
Number of participants (Planned and analyzed)
Single-center open-label enrollment of 24 participants in three cohorts
Description of analysis sets
Descriptive statistics and external Caucasian data in the single-dose plots
Results
Participant disposition
Reason for the single discontinuation due to a treatment-emergent adverse event
Baseline characteristics
Demographics by ethnic cohort
| Characteristic | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) | Overall (n=24) |
|---|---|---|---|---|
| Age (years), mean (SD) | “42.6 (9.3)” | “38.4 (8.2)” | “45.5 (11.8)” | “42.2 (9.9)” |
| Sex, female/male, n (%) | “1 (12.5)/7 (87.5)” | “0 (0.0)/8 (100.0)” | “5 (62.5)/3 (37.5)” | “6 (25.0)/18 (75.0)” |
| Hispanic or Latino, n (%) | “0 (0.0)” | “0 (0.0)” | “2 (25.0)” | “2 (8.3)” |
| Not Hispanic or Latino, n (%) | “8 (100.0)” | “8 (100.0)” | “6 (75.0)” | “22 (91.7)” |
| Height (cm), mean (SD) | “170.2 (8.2)” | “170.0 (3.0)” | “168.6 (7.7)” | “169.6 (6.4)” |
| Weight (kg), mean (SD) | “66.4 (10.2)” | “72.6 (9.7)” | “80.4 (8.1)” | “73.1 (10.7)” |
Efficacy results
Steady-state pharmacokinetics of the parent drug and main metabolite on day 7 of 40 mg twice daily, by ethnic cohort
| Parameter | Cohort 1: Japanese (n=8) | Cohort 2: Chinese (n=8) | Cohort 3: Caucasian (n=8) |
|---|---|---|---|
| Cmax,ss (ng/mL), geometric mean (CV%) | “502 (25.1)” | “586 (24.3)” | “531 (11.1)” |
| AUC0-τ,ss (hr*ng/mL), geometric mean (CV%) | “3,410 (22.7)” | “4,580 (18.3)” | “3,530 (9.5)” |
| Tmax,ss (hr), median (min, max) | “2.8 (2.0, 4.0)” | “3.0 (1.0, 6.0)” | “1.0 (1.0, 2.0)” |
| t1/2,ss (hr), geometric mean (CV%) | “7.6 (20.4)” | “8.4 (13.4)” | “9.1 (17.0)” |
| CL/F (L/hr), geometric mean (CV%) | “10.8 (22.7)” | “8.0 (18.3)” | “10.4 (9.5)” |
| Vd/F (L), geometric mean (CV%) | “118.0 (35.9)” | “97.4 (26.5)” | “138.0 (17.7)” |
| BWCmax (ng/mL/mg/kg), geometric mean (CV%) | “895 (32.5)” | “1,140 (14.3)” | “1,140 (12.6)” |
| BWAUC0-τ,ss (hr*ng/mL/mg/kg), geometric mean (CV%) | “6,080 (26.9)” | “8,950 (9.8)” | “7,540 (11.4)” |
| Rac, geometric mean (CV%) | “2.10 (96.3)” | “2.48 (38.0)” | “2.09 (34.7)” |
| MRCmax main metabolite, geometric mean (CV%) | “2.65 (33.6)” | “2.91 (23.1)” | “2.60 (24.9)” |
| MRAUC main metabolite, geometric mean (CV%) | “3.56 (30.3)” | “3.69 (24.9)” | “3.73 (15.8)” |
Comparability of absorption, exposure, elimination, and food effect across ethnicities
Conclusion on dosing in Asian populations
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by dose period and ethnic cohort
| Event | 20 mg, Japanese (n=8) | 20 mg, Chinese (n=8) | 40 mg, Japanese (n=8) | 40 mg, Chinese (n=8) | 40 mg BID, Japanese (n=8) | 40 mg BID, Chinese (n=8) | 40 mg BID, Caucasian (n=8) |
|---|---|---|---|---|---|---|---|
| Any TEAE, n (%) | “1 (12.5)” | “2 (25.0)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “5 (62.5)” | “6 (75.0)” |
| At least 1 TEAE Grade 2, n (%) | “0 (0.0)” | “1 (12.5)” | “0 (0.0)” | “1 (12.5)” | “1 (12.5)” | “0 (0.0)” | “4 (50.0)” |
| At least 1 TEAE Grade ≥3, n (%) | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| TEAE related to study medication | “1 (12.5)” | “1 (12.5)” | “5 (62.5)” | “1 (12.5)” | “4 (50.0)” | “4 (50.0)” | “6 (75.0)” |
| TEAEs leading to study discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |
| TEAEs leading to study medication discontinuation | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (12.5)” |
Tolerability, severity, and most common events by ethnic cohort
Study limitations
Summary
- The only source is one congress poster; no registry record, study location, or study dates are quoted, and the poster states no limitations.
- The study was single-center and open-label, with 24 healthy participants (8 per cohort).
- The Caucasian cohort received only 40 mg BID, and the Caucasian single-dose curves were plotted with data from another study (ESK-001-003).
- Day 7 pharmacokinetic profiles of the twice-daily regimen were obtained in the fed state for the Japanese and Chinese cohorts and in the fasted state for the Caucasian cohort.
- The cohorts differed in sex (female/male: 1/7, 0/8, and 5/3) and mean weight (66.4, 72.6, and 80.4 kg), and the results are descriptive statistics that are not log-transformed.
ESK-001-019
Objective
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2024-06-21” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2024-08-31” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2024-08-31” (opens the source at this quote in a new tab)
“First Submitted 2025-12-10” (opens the source at this quote in a new tab)
“First Posted 2026-01-30” (opens the source at this quote in a new tab)
Site in Daytona Beach, Florida, in the ClinicalTrials.gov record
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-01-30” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-019” |
| Conditions | “Healthy Volunteer” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “Triple (ParticipantInvestigatorOutcomes Assessor)” |
Four treatment sequences, blinding, and central electrocardiogram reading
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using placebo-adjusted change in QTcF as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- The study is known only from its ClinicalTrials.gov record, which reads “No Results Posted”; the report holds no QTcF, ECG, pharmacokinetic, or safety result.
- The record was first submitted on 2025-12-10, after the actual study completion date of 2024-08-31.
- The record describes the therapeutic and supratherapeutic arms each as one oral dose of ESK-001 without stating the dose.
- The study gave single doses to 52 healthy participants aged 18 to 55 years at one site, with the moxifloxacin positive control given open label.
ESK-001-022
Objective
Brief summary in the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2025-04-29” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-03-24” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2026-03-24” (opens the source at this quote in a new tab)
“First Posted 2025-05-01” (opens the source at this quote in a new tab)
Completion dates estimated at registration, April 2025, superseded in May 2026
Sites in California, Florida, and Tennessee in the ClinicalTrials.gov record
| Site | Quoted record |
|---|---|
| California | “Lake Forest, California, United States, 92630” |
| Florida | “Miami Lakes, Florida, United States, 33104” |
| Florida | “Orlando, Florida, United States, 32809” |
| Tennessee | “Knoxville, Tennessee, United States, 37920” |
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-05-12” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-022” |
| Conditions | “Hepatic Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, April 2025, superseded in May 2026
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- The hepatic impairment study has no posted results, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- The design is open-label and non-randomized, with one dose of ESK-001 of unstated strength and a 48-hour outcome time frame.
- Actual enrollment was 32 participants, against 48 estimated at registration and a planned structure of up to 24 healthy volunteers and 8 participants each with mild, moderate, and severe hepatic impairment; the number enrolled in each group is not reported.
ESK-001-023
Objective
Brief summary in the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2025-04-23” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-08-01” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-08-01” (opens the source at this quote in a new tab)
“First Posted 2025-05-08” (opens the source at this quote in a new tab)
Start and completion dates estimated at registration, April 2025, superseded in December 2025
Sites in Florida in the ClinicalTrials.gov record
| Site | Quoted record |
|---|---|
| Florida | “Miami, Florida, United States, 33147” |
| Florida | “Miami Lakes, Florida, United States, 33014” |
| Florida | “Miami Lakes, Florida, United States, 33016” |
| Florida | “Orlando, Florida, United States, 32809” |
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2025-12-10” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-023” |
| Conditions | “Renal Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Participant)” |
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using pharmacokinetic parameters and adverse event incidence as the primary endpoints
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, April 2025, superseded in December 2025
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- No pharmacokinetic or adverse event results of the renal impairment study have been posted, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- Only participants were masked, allocation was non-randomized, and each participant received a single dose with outcomes assessed over 48 hours.
- Enrollment was 16 participants, against 48 estimated at registration, at four sites in Florida; the record plans 8 participants each with mild, moderate, and severe renal impairment but does not report how many were enrolled in each group, and participants requiring dialysis were not eligible.
ESK-001-002
Objective
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2022-03-17” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2022-06-30” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2022-09-20” (opens the source at this quote in a new tab)
“First Submitted 2022-03-30” (opens the source at this quote in a new tab)
“First Posted 2022-04-15” (opens the source at this quote in a new tab)
Completion dates estimated at registration, April 2022, superseded in September 2022
Site in Glendale, California, in the ClinicalTrials.gov record
“This study has 1 location” (opens the source at this quote in a new tab)
“Alumis Central Site” (opens the source at this quote in a new tab)
| Field | Quoted record |
|---|---|
| Location | “Glendale, California, United States, 91206” |
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-002” |
| Conditions | “Pharmacokinetics” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
Four-period crossover with an 18-day stay in the clinical research unit in the registered description
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Inclusion: age and health | “Healthy Men and woman age 18-60” |
| Inclusion: consent | “Able to provide written informed consent” |
| Inclusion: pregnancy and lactation | “Females can not be pregnant or lactating” |
| Exclusion: prior exposure | “Prior exposure to ESK-001” |
| Exclusion: malignancy | “History of malignancy within the last 10 years” |
| Exclusion: viral infection | “Positive for HIV, Hepatitis B or C” |
| Exclusion: tuberculosis | “History of tuberculosis” |
| Exclusion: alcohol or drugs | “Positive test for alcohol or drugs” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Liquid, fasted tablet, fed tablet, and tablet with rabeprazole arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, April 2022, superseded in May 2023
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- The relative bioavailability, food effect, and gastric acid reduction comparisons (liquid, tablet fasted, tablet fed, and tablet with rabeprazole) have no posted results, and the report holds no published results; the ClinicalTrials.gov record reads “No Results Posted”.
- The study was a single-center, open-label crossover study; the registered description calls it partly randomized and plans 15 healthy participants, and actual enrollment was 14.
- Each participant received a single dose on 4 occasions, so the comparisons rest on single-dose pharmacokinetics in healthy adults aged 18 to 60 years.